Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Delcath Systems stock

Learn how to easily invest in Delcath Systems stock.

Delcath Systems Inc is a medical devices business based in the US. Delcath Systems shares (DCTH) are listed on the NASDAQ and all prices are listed in US Dollars. Delcath Systems employs 55 staff and has a trailing 12-month revenue of around $3.8 million.

How to buy shares in Delcath Systems

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DCTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Delcath Systems stock price (NASDAQ: DCTH)

Use our graph to track the performance of DCTH stocks over time.

Delcath Systems shares at a glance

Information last updated 2022-10-02.
Latest market close$3.27
52-week range$2.98 - $11.95
50-day moving average $4.07
200-day moving average $5.44
Wall St. target price$18.60
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.58

Buy Delcath Systems shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Delcath Systems stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Delcath Systems price performance over time

Historical closes compared with the close of $3.27 from 2022-10-03

1 week (2022-09-28) 5.48%
1 month (2022-09-02) -22.51%
3 months (2022-07-05) -16.37%
6 months (2022-04-05) -48.91%
1 year (2021-10-05) -65.43%
2 years (2020-10-05) -72.43%
3 years (2019-10-04) 3,320.50%
5 years (2017-10-04) 5,260.66%

Delcath Systems financials

Revenue TTM $3.8 million
Gross profit TTM $2.9 million
Return on assets TTM -75.79%
Return on equity TTM -492.68%
Profit margin 0%
Book value $0.66
Market capitalisation $27.5 million

TTM: trailing 12 months

Delcath Systems share dividends

We're not expecting Delcath Systems to pay a dividend over the next 12 months.

Have Delcath Systems's shares ever split?

Delcath Systems's shares were split on a 1:700 basis on 23 December 2019. So if you had owned 700 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Delcath Systems shares – just the quantity. However, indirectly, the new 69900% higher share price could have impacted the market appetite for Delcath Systems shares which in turn could have impacted Delcath Systems's share price.

Delcath Systems share price volatility

Over the last 12 months, Delcath Systems's shares have ranged in value from as little as $2.9782 up to $11.9517. A popular way to gauge a stock's volatility is its "beta".

DCTH.US volatility(beta: 0.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Delcath Systems's is 0.8797. This would suggest that Delcath Systems's shares are less volatile than average (for this exchange).

Delcath Systems overview

Delcath Systems, Inc. , an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Frequently asked questions

What percentage of Delcath Systems is owned by insiders or institutions?
Currently 2.428% of Delcath Systems shares are held by insiders and 19.384% by institutions.
How many people work for Delcath Systems?
Latest data suggests 55 work at Delcath Systems.
When does the fiscal year end for Delcath Systems?
Delcath Systems's fiscal year ends in December.
Where is Delcath Systems based?
Delcath Systems's address is: 1633 Broadway, New York, NY, United States, 10019
What is Delcath Systems's ISIN number?
Delcath Systems's international securities identification number is: US24661P8077

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site